60 Degrees Pharmaceuticals announced that it has signed clinical trial agreements with all three planned clinical trial sites for the Tafenoquine for Babesiosis trial, which is now enrolling. Tufts Medical Center, Yale University and Rhode Island Hospital will conduct the world’s first randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of tafenoquine in the treatment of human babesiosis patients. At least 24 and potentially up to 33 hospitalized patients diagnosed with recurrent babesiosis will be recruited for the study, with interim results expected in September 2025.